Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

Background The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against clinical malaria for at least 21 months in a trial in Mozambican children. Efficacy varied between different endpoints, such as parasitaemia or clinical malaria; however the underlying mechanisms that determine efficacy and its duration remain unknown. We performed a new, exploratory analysis to explore differences in the duration of protection among participants to better understand the protection afforded by RTS,S. Methodology/Principal Findings The study was a Phase IIb double-blind, randomized controlled trial in 2022 children aged 1 to 4 years. The trial was designed with two cohorts to estimate vaccine efficacy against two different endpoints: clinical malaria (cohort 1) and infection (cohort 2). Participants were randomly allocated to receive three doses of RTS,S/AS02A or control vaccines. We did a retrospective, unplanned sub-analysis of cohort 2 data using information collected for safety through the health facility-based passive case detection system. Vaccine efficacy against clinical malaria was estimated over the first six-month surveillance period (double-blind phase) and over the following 12 months (single-blind phase), and analysis was per-protocol. Adjusted vaccine efficacy against first clinical malaria episodes in cohort 2 was of 35.4% (95% CI 4.5–56.3; p = 0.029) over the double-blind phase and of 9.0% (−30.6–36.6; p = 0.609) during the single-blind phase. Conclusions/Significance Contrary to observations in cohort 1, where efficacy against clinical malaria did not wane over time, in cohort 2 the efficacy decreases with time. We hypothesize that this reduced duration of protection is a result of the early diagnosis and treatment of infections in cohort 2 participants, preventing sufficient exposure to asexual-stage antigens. On the other hand, the long-term protection against clinical disease observed in cohort 1 may be a consequence of a prolonged exposure to low-dose blood-stage asexual parasitaemia. Trial Registration ClinicalTrials.gov NCT00197041

[1]  M. Demoitié,et al.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.

[2]  M. Tanner,et al.  Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. , 2008, The New England journal of medicine.

[3]  C. John,et al.  Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. , 2008, The Journal of infectious diseases.

[4]  C. Drakeley,et al.  How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? , 2007, Malaria Journal.

[5]  P. Alonso,et al.  Methods for determining vaccine efficacy and effectiveness and the main barriers to developing a fully deployable malaria vaccine. , 2007, The American journal of tropical medicine and hygiene.

[6]  Q. Bassat,et al.  Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial , 2007, The Lancet.

[7]  Peter G. Smith,et al.  Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. , 2007, Vaccine.

[8]  Q. Bassat,et al.  Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial , 2005, The Lancet.

[9]  M. Tanner,et al.  Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial , 2005, The Lancet.

[10]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[11]  M. Dgedge,et al.  Malaria in southern Mozambique: malariometric indicators and malaria case definition in Manhiça district. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  Danny W. Wilson,et al.  Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum , 2002, The Lancet.

[13]  Patricia De la Vega,et al.  Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.

[14]  D. Conway,et al.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial , 2001, The Lancet.

[15]  S. Hoffman,et al.  Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. , 2001, The American journal of tropical medicine and hygiene.

[16]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[17]  A. Monroy-Ostria,et al.  Plasmodium chabaudi chabaudi: effect of low parasitemias on immunity in CB6F1 mice. , 1999, Experimental parasitology.

[18]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[19]  K R Hess,et al.  Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. , 1995, Statistics in medicine.

[20]  T. Smith,et al.  Attributable fraction estimates and case definitions for malaria in endemic areas. , 1994, Statistics in medicine.

[21]  J. F. Young,et al.  Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. , 1987, Experimental parasitology.

[22]  H. Masanja.  Randomised trial of efficacy of SPf 66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania Summary , 2003 .